Pular para o conteúdo
Carcinoma da tireoide raro
ORPHA:100088DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
Sistema ósseoInício adulta

Carcinoma originado da glândula tireóide. Geralmente é um adenocarcinoma e inclui os seguintes subtipos principais: folicular, papilar, medular, pouco diferenciado e anaplásico.

Em construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

O carcinoma da tireoide raro é um tipo incomum de tumor que se desenvolve na glândula tireoide, acometendo principalmente pessoas na fase adulta. Ele costuma provocar alterações no pescoço, rouquidão, dificuldade nas vias respiratórias e dores no corpo. No Brasil, esta condição não faz parte da lista oficial de protocolos clínicos e diretrizes terapêuticas (PCDT) de doenças raras do Ministério da Saúde. O acompanhamento médico é realizado por meio dos serviços de referência da rede oncológica do Sistema Único de Saúde.

📋
Informacoes curadas por IA — podem conter imprecisoes

Carcinoma originado da glândula tireóide. Geralmente é um adenocarcinoma e inclui os seguintes subtipos principais: folicular, papilar, medular, pouco diferenciado e anaplásico.

Pesquisas ativas
23 ensaios
43 total registrados no ClinicalTrials.gov
Publicações científicas
11 artigos
Último publicado: 2026 Apr

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
12.7
Worldwide
Início
Adult
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
13 sintomas
🦴
Ossos e articulações
11 sintomas
🫘
Rins
10 sintomas
🫃
Digestivo
9 sintomas
🧠
Neurológico
8 sintomas
🫁
Pulmão
7 sintomas

+ 38 sintomas em outras categorias

Características mais comuns

—
Dor torácica
—
Dor óssea
—
Carcinoma anaplásico de tireoide
—
Hiperidrose
—
Pé cavo
—
Morfologia anormal do músculo esquelético
111sintomas
Sem dados (111)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 111 características clínicas mais associadas, ordenadas por frequência.

Dor torácicaChest pain
Dor ósseaBone pain
Carcinoma anaplásico de tireoideAnaplastic thyroid carcinoma
HiperidroseHyperhidrosis
Pé cavoPes cavus

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico11PubMed
Últimos 10 anos9publicações
Pico20222 papers
Linha do tempo
2026Hoje · 2026🧪 2006Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

33 genes identificados com associação a esta condição.

LPAR4Lysophosphatidic acid receptor 4Candidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
G alpha (q) signalling eventsP2Y receptors
EXPRESSÃO TECIDUAL(Baixa expressão)
Ovário
3.0 TPM
Esôfago - Junção
1.2 TPM
Útero
0.9 TPM
Cervix Endocervix
0.8 TPM
Esôfago - Muscular
0.7 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:4478UniProt:Q99677
MINPP1Multiple inositol polyphosphate phosphatase 1Candidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Synthesis of IPs in the ER lumen
MECANISMO DE DOENÇA

Thyroid cancer, non-medullary, 2

A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
34.1 TPM
Glândula adrenal
24.9 TPM
Ovário
14.8 TPM
Linfócitos
14.0 TPM
Pulmão
13.4 TPM
OUTRAS DOENÇAS (4)
pontocerebellar hypoplasia, type 16familial papillary or follicular thyroid carcinomapontocerebellar hypoplasia type 7thyroid cancer, nonmedullary, 2
HGNC:7102UniProt:Q9UNW1
NDUFA13NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Candidate gene tested inTolerante
VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial protein degradation
MECANISMO DE DOENÇA

Hurthle cell thyroid carcinoma

A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
261.5 TPM
Coração - Ventrículo esquerdo
190.8 TPM
Coração - Átrio
181.5 TPM
Pituitária
162.4 TPM
Brain Frontal Cortex BA9
149.7 TPM
OUTRAS DOENÇAS (3)
mitochondrial complex I deficiency, nuclear type 28differentiated thyroid carcinomathyroid Hurthle cell carcinoma
HGNC:17194UniProt:Q9P0J0
TPRNucleoprotein TPRCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (10)
snRNP AssemblyHCMV Early EventsHCMV Late EventsNEP/NS2 Interacts with the Cellular Export MachineryTransport of Ribonucleoproteins into the Host Nucleus
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
75.9 TPM
Linfócitos
72.8 TPM
Fibroblastos
64.6 TPM
Tireoide
48.7 TPM
Ovário
48.7 TPM
OUTRAS DOENÇAS (3)
intellectual developmental disorder, autosomal recessive 79autosomal recessive non-syndromic intellectual disabilitydifferentiated thyroid carcinoma
HGNC:12017UniProt:P12270
ESR2Estrogen receptor betaCandidate gene tested inTolerante
VIAS BIOLÓGICAS (4)
PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingPIP3 activates AKT signalingConstitutive Signaling by Aberrant PI3K in CancerExtra-nuclear estrogen signaling
MECANISMO DE DOENÇA

Ovarian dysgenesis 8

An autosomal dominant form of ovarian dysgenesis, a disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads.

EXPRESSÃO TECIDUAL(Baixa expressão)
Ovário
4.6 TPM
Testículo
3.9 TPM
Glândula adrenal
3.6 TPM
Linfócitos
2.3 TPM
Cervix Endocervix
1.4 TPM
OUTRAS DOENÇAS (2)
ovarian dysgenesis 8familial medullary thyroid carcinoma
HGNC:3468UniProt:Q92731
NRASGTPase NRasDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsNeutrophil degranulation
MECANISMO DE DOENÇA

Leukemia, juvenile myelomonocytic

An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
77.3 TPM
Fibroblastos
52.5 TPM
Skin Not Sun Exposed Suprapubic
25.1 TPM
Esôfago - Mucosa
24.4 TPM
Skin Sun Exposed Lower leg
23.4 TPM
OUTRAS DOENÇAS (13)
neurocutaneous melanocytosislarge congenital melanocytic nevusthyroid cancer, nonmedullary, 2colorectal cancer
HGNC:7989UniProt:P01111
GAS8-AS1Uncharacterized protein GAS8-AS1Candidate gene tested inDesconhecido
VIAS BIOLÓGICAS (1)
Activation of SMO
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:1197UniProt:O95177
PAX8Paired box protein Pax-8Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (2)
Formation of the nephric ductFormation of intermediate mesoderm
MECANISMO DE DOENÇA

Hypothyroidism, congenital, non-goitrous, 2

A disease characterized by thyroid dysgenesis, the most frequent cause of congenital hypothyroidism, accounting for 85% of case. The thyroid gland can be completely absent (athyreosis), ectopically located and/or severely hypoplastic. Ectopic thyroid gland is the most frequent malformation, with thyroid tissue being found most often at the base of the tongue.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
1192.7 TPM
Rim - Medula
275.9 TPM
Rim - Córtex
170.0 TPM
Fallopian Tube
28.9 TPM
Glândula adrenal
5.5 TPM
OUTRAS DOENÇAS (5)
hypothyroidism, congenital, nongoitrous, 2thyroid hypoplasiaathyreosisdifferentiated thyroid carcinoma
HGNC:8622UniProt:Q06710
BRAFSerine/threonine-protein kinase B-rafCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (4)
Spry regulation of FGF signalingParadoxical activation of RAF signaling by kinase inactive BRAFARMS-mediated activationSignalling to p38 via RIT and RIN
OUTRAS DOENÇAS (18)
Noonan syndrome 7LEOPARD syndrome 3melanoma, cutaneous malignant, susceptibility to, 1lung cancer
HGNC:1097UniProt:P15056
NKX2-1Homeobox protein Nkx-2.1Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (2)
Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cellsRegulation of gene expression in beta cells
MECANISMO DE DOENÇA

Chorea, hereditary benign

A rare autosomal dominant movement disorder, defined by early onset in childhood, a stable or non-progressive course of chorea, and no mental deterioration. Chorea is characterized by involuntary, forcible, rapid, jerky movements that may be subtle or become confluent, markedly altering normal patterns of movement.

EXPRESSÃO TECIDUAL(Tecido-específico)
Tireoide
352.6 TPM
Pulmão
89.7 TPM
Hipotálamo
5.6 TPM
Brain Caudate basal ganglia
3.5 TPM
Brain Nucleus accumbens basal ganglia
3.3 TPM
OUTRAS DOENÇAS (6)
brain-lung-thyroid syndromehereditary progressive chorea without dementiaathyreosisdifferentiated thyroid carcinoma
HGNC:11825UniProt:P43699
NTRK3NT-3 growth factor receptorCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (4)
NTF3 activates NTRK3 signalingSignaling by NTRK3 (TRKC)NTRK3 as a dependence receptorReceptor-type tyrosine-protein phosphatases
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
32.5 TPM
Artéria coronária
22.1 TPM
Aorta
21.6 TPM
Cerebelo
15.8 TPM
Cérebro - Hemisfério cerebelar
13.9 TPM
OUTRAS DOENÇAS (3)
congenital mesoblastic nephromadifferentiated thyroid carcinomafibrosarcoma
HGNC:8033UniProt:Q16288
HABP2Factor VII-activating proteaseCandidate gene tested inTolerante
MECANISMO DE DOENÇA

Thyroid cancer, non-medullary, 5

A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
120.6 TPM
Rim - Córtex
8.6 TPM
Pâncreas
6.3 TPM
Rim - Medula
3.6 TPM
Estômago
2.3 TPM
OUTRAS DOENÇAS (3)
familial papillary or follicular thyroid carcinomathrombophilia due to thrombin defectthyroid cancer, nonmedullary, 5
HGNC:4798UniProt:Q14520
EIF1AXEukaryotic translation initiation factor 1A, X-chromosomalCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (6)
Translation initiation complex formationRibosomal scanning and start codon recognitionGTP hydrolysis and joining of the 60S ribosomal subunitL13a-mediated translational silencing of Ceruloplasmin expressionFormation of the ternary complex, and subsequently, the 43S complex
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
82.9 TPM
Ovário
72.0 TPM
Útero
71.4 TPM
Cervix Ectocervix
60.4 TPM
Fallopian Tube
60.4 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:3250UniProt:P47813
SRGAP1SLIT-ROBO Rho GTPase-activating protein 1Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (4)
Inactivation of CDC42 and RAC1RAC1 GTPase cycleCDC42 GTPase cycleRHOA GTPase cycle
MECANISMO DE DOENÇA

Thyroid cancer, non-medullary, 2

A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
11.4 TPM
Cervix Ectocervix
4.8 TPM
Nervo tibial
4.6 TPM
Pulmão
4.2 TPM
Cervix Endocervix
4.0 TPM
OUTRAS DOENÇAS (1)
thyroid cancer, nonmedullary, 2
HGNC:HGNC:17382UniProt:Q7Z6B7
NTRK1High affinity nerve growth factor receptorCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
TRKA activation by NGF
MECANISMO DE DOENÇA

Congenital insensitivity to pain with anhidrosis

Characterized by a congenital insensitivity to pain, anhidrosis (absence of sweating), absence of reaction to noxious stimuli, self-mutilating behavior, and intellectual disability. This rare autosomal recessive disorder is also known as congenital sensory neuropathy with anhidrosis or hereditary sensory and autonomic neuropathy type IV or familial dysautonomia type II.

EXPRESSÃO TECIDUAL(Tecido-específico)
Próstata
5.7 TPM
Testículo
4.9 TPM
Cervix Endocervix
4.3 TPM
Útero
3.7 TPM
Fallopian Tube
3.5 TPM
OUTRAS DOENÇAS (4)
hereditary sensory and autonomic neuropathy type 4hereditary sensory and autonomic neuropathy type 5familial medullary thyroid carcinomadifferentiated thyroid carcinoma
HGNC:8031UniProt:P04629
TRIM33E3 ubiquitin-protein ligase TRIM33Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (2)
Downregulation of SMAD2/3:SMAD4 transcriptional activityGerm layer formation at gastrulation
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
26.0 TPM
Cérebro - Hemisfério cerebelar
25.6 TPM
Útero
23.2 TPM
Ovário
22.6 TPM
Nervo tibial
21.8 TPM
OUTRAS DOENÇAS (2)
differentiated thyroid carcinomadislocation of the hip-dysmorphism syndrome
HGNC:16290UniProt:Q9UPN9
PCM1Pericentriolar material 1 proteinCandidate gene tested inTolerante
VIAS BIOLÓGICAS (7)
Recruitment of mitotic centrosome proteins and complexesLoss of proteins required for interphase microtubule organization from the centrosomeLoss of Nlp from mitotic centrosomesRegulation of PLK1 Activity at G2/M TransitionAURKA Activation by TPX2
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
106.3 TPM
Linfócitos
63.2 TPM
Ovário
55.1 TPM
Cérebro - Hemisfério cerebelar
49.3 TPM
Útero
48.2 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:8727UniProt:Q15154
GOLGA5Golgin subfamily A member 5Candidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Intra-Golgi traffic
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
80.9 TPM
Testículo
55.1 TPM
Artéria tibial
49.1 TPM
Aorta
47.0 TPM
Tecido adiposo
45.9 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:4428UniProt:Q8TBA6
ETV6Transcription factor ETV6Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (1)
Signaling by FLT3 fusion proteins
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
45.0 TPM
Glândula salivar
42.7 TPM
Skin Sun Exposed Lower leg
35.5 TPM
Linfócitos
30.0 TPM
Aorta
29.4 TPM
OUTRAS DOENÇAS (9)
acute myeloid leukemiathrombocytopenia 5B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1)obsolete autosomal thrombocytopenia with normal platelets
HGNC:3495UniProt:P41212
CCDC6Coiled-coil domain-containing protein 6Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (1)
Signaling by FGFR2 fusions
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:18782UniProt:Q16204
RETProto-oncogene tyrosine-protein kinase receptor RetDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (4)
RET signalingFormation of the ureteric budFormation of the nephric ductNPAS4 regulates expression of target genes
MECANISMO DE DOENÇA

Hirschsprung disease 1

A disorder of neural crest development characterized by absence of enteric ganglia along a variable length of the intestine. It is the most common cause of congenital intestinal obstruction. Early symptoms range from complete acute neonatal obstruction, characterized by vomiting, abdominal distention and failure to pass stool, to chronic constipation in the older child.

EXPRESSÃO TECIDUAL(Tecido-específico)
Substância negra
6.3 TPM
Pituitária
4.8 TPM
Cerebelo
4.0 TPM
Cólon sigmoide
4.0 TPM
Brain Frontal Cortex BA9
3.8 TPM
OUTRAS DOENÇAS (12)
multiple endocrine neoplasia type 2Bpheochromocytomafamilial medullary thyroid carcinomamultiple endocrine neoplasia type 2A
HGNC:9967UniProt:P07949
DIRC3Candidate gene tested inDesconhecido
OUTRAS DOENÇAS (2)
differentiated thyroid carcinomahereditary clear cell renal cell carcinoma
HGNC:17805
KRASGTPase KRasCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsRUNX3 regulates p14-ARF
MECANISMO DE DOENÇA

Leukemia, acute myelogenous

A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
30.7 TPM
Cérebro - Hemisfério cerebelar
25.1 TPM
Esôfago - Muscular
22.2 TPM
Esôfago - Mucosa
21.6 TPM
Esôfago - Junção
20.2 TPM
OUTRAS DOENÇAS (20)
gastric canceracute myeloid leukemialinear nevus sebaceous syndromeNoonan syndrome 3
HGNC:6407UniProt:P01116
HRASGTPase HRasDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsEPHB-mediated forward signaling
MECANISMO DE DOENÇA

Costello syndrome

A rare condition characterized by prenatally increased growth, postnatal growth deficiency, intellectual disability, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Not Sun Exposed Suprapubic
107.7 TPM
Skin Sun Exposed Lower leg
104.9 TPM
Esôfago - Mucosa
81.3 TPM
Cérebro - Hemisfério cerebelar
77.6 TPM
Brain Caudate basal ganglia
77.6 TPM
OUTRAS DOENÇAS (10)
nevus, epidermalthyroid cancer, nonmedullary, 2Costello syndromelinear nevus sebaceous syndrome
HGNC:5173UniProt:P01112
ERC1ELKS/Rab6-interacting/CAST family member 1Candidate gene tested inRestrito
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
34.8 TPM
Cerebelo
32.7 TPM
Artéria tibial
25.6 TPM
Aorta
21.0 TPM
Esôfago - Muscular
20.6 TPM
OUTRAS DOENÇAS (2)
distal monosomy 12pdifferentiated thyroid carcinoma
HGNC:17072UniProt:Q8IUD2
TERTTelomerase reverse transcriptaseCandidate gene tested inRestrito
VIAS BIOLÓGICAS (3)
Telomere Extension By TelomeraseFormation of the beta-catenin:TCF transactivating complexRegulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence
EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
2.7 TPM
Intestino delgado
0.7 TPM
Brain Caudate basal ganglia
0.6 TPM
Cólon transverso
0.5 TPM
Brain Nucleus accumbens basal ganglia
0.5 TPM
OUTRAS DOENÇAS (13)
dyskeratosis congenita, autosomal dominant 2pulmonary fibrosis and/or bone marrow failure, Telomere-related, 1adrenal cortex carcinomaclear cell sarcoma of kidney
HGNC:11730UniProt:O14746
FOXE1Forkhead box protein E1Candidate gene tested inTolerante
MECANISMO DE DOENÇA

Bamforth-Lazarus syndrome

An autosomal recessive disease characterized by congenital hypothyroidism due to thyroid agenesis or thyroid hypoplasia, cleft palate, spiky hair, with or without choanal atresia, and bifid epiglottis.

EXPRESSÃO TECIDUAL(Tecido-específico)
Tireoide
164.5 TPM
Esôfago - Mucosa
8.2 TPM
Vagina
6.1 TPM
Testículo
1.1 TPM
Skin Not Sun Exposed Suprapubic
1.0 TPM
OUTRAS DOENÇAS (5)
Bamforth-Lazarus syndromedifferentiated thyroid carcinomafamilial papillary or follicular thyroid carcinomaathyreosis
HGNC:3806UniProt:O00358
ALKALK tyrosine kinase receptorCandidate gene tested inRestrito
VIAS BIOLÓGICAS (2)
Signaling by ALKMDK and PTN in ALK signaling
OUTRAS DOENÇAS (9)
large congenital melanocytic nevusneuroblastomaganglioneuroblastomadifferentiated thyroid carcinoma
HGNC:427UniProt:Q9UM73
TRIM24Transcription intermediary factor 1-alphaCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (2)
Signaling by FGFR1 in diseaseSignaling by cytosolic FGFR1 fusion mutants
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
20.9 TPM
Glândula adrenal
19.9 TPM
Ovário
16.5 TPM
Linfócitos
9.1 TPM
Próstata
7.9 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:11812UniProt:O15164
TRIM27Zinc finger protein RFPCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (2)
Regulation of PTEN stability and activitySuppression of apoptosis
EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
61.2 TPM
Fallopian Tube
55.1 TPM
Baço
54.4 TPM
Cervix Ectocervix
53.1 TPM
Útero
49.7 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:9975UniProt:P14373
TFGProtein TFGCandidate gene tested inModerado
VIAS BIOLÓGICAS (1)
COPII-mediated vesicle transport
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
86.6 TPM
Linfócitos
61.6 TPM
Tireoide
60.1 TPM
Nervo tibial
55.3 TPM
Aorta
53.8 TPM
OUTRAS DOENÇAS (5)
hereditary motor and sensory neuropathy, Okinawa typehereditary spastic paraplegia 57autosomal dominant Charcot-Marie-Tooth disease type 2 due to TFG mutationdifferentiated thyroid carcinoma
HGNC:11758UniProt:Q92734
NCOA4Nuclear receptor coactivator 4Candidate gene tested inTolerante
EXPRESSÃO TECIDUAL(Ubíquo)
Baço
122.0 TPM
Fibroblastos
117.3 TPM
Artéria tibial
110.7 TPM
Bladder
108.6 TPM
Esôfago - Muscular
102.7 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:7671UniProt:Q13772
PPARGPeroxisome proliferator-activated receptor gammaCandidate gene tested inModerado
VIAS BIOLÓGICAS (7)
Regulation of PTEN gene transcriptionTranscriptional regulation of white adipocyte differentiationPPARA activates gene expressionMECP2 regulates transcription factorsNuclear Receptor transcription pathway
EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
111.2 TPM
Adipose Visceral Omentum
100.8 TPM
Mama
71.3 TPM
Cólon transverso
21.6 TPM
Fibroblastos
20.4 TPM
OUTRAS DOENÇAS (6)
type 2 diabetes mellitusPPARG-related familial partial lipodystrophyinherited obesitygliosarcoma
HGNC:9236UniProt:P37231

Variantes genéticas (ClinVar)

195 variantes patogênicas registradas no ClinVar.

🧬 LPAR4: GRCh37/hg19 Xq13.1-22.2(chrX:70460290-103312921)x3 ()
🧬 LPAR4: GRCh37/hg19 Xq21.1-22.3(chrX:77574432-106660031)x1 ()
🧬 LPAR4: GRCh37/hg19 Xq13.1-22.3(chrX:69013433-104620838)x2 ()
🧬 LPAR4: GRCh37/hg19 Xq13.1-27.1(chrX:71017904-140066710)x4 ()
🧬 LPAR4: GRCh37/hg19 Xq13.1-22.2(chrX:70460290-103312921)x4 ()
Ver todas no ClinVar

Vias biológicas (Reactome)

174 vias biológicas associadas aos genes desta condição.

G alpha (q) signalling events P2Y receptors Synthesis of IPs in the ER lumen Respiratory electron transport Complex I biogenesis Mitochondrial protein degradation ISG15 antiviral mechanism Transport of the SLBP independent Mature mRNA Transport of the SLBP Dependant Mature mRNA Transport of Mature mRNA Derived from an Intronless Transcript Transport of Mature mRNA derived from an Intron-Containing Transcript Rev-mediated nuclear export of HIV RNA Transport of Ribonucleoproteins into the Host Nucleus NS1 Mediated Effects on Host Pathways Viral Messenger RNA Synthesis NEP/NS2 Interacts with the Cellular Export Machinery Regulation of Glucokinase by Glucokinase Regulatory Protein Nuclear import of Rev protein Vpr-mediated nuclear import of PICs snRNP Assembly SUMOylation of DNA damage response and repair proteins SUMOylation of ubiquitinylation proteins Nuclear Pore Complex (NPC) Disassembly Regulation of HSF1-mediated heat shock response SUMOylation of SUMOylation proteins SUMOylation of chromatin organization proteins SUMOylation of RNA binding proteins SUMOylation of DNA replication proteins Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) tRNA processing in the nucleus HCMV Early Events HCMV Late Events SARS-CoV-2 activates/modulates innate and adaptive immune responses Signaling by ALK fusions and activated point mutants PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Nuclear Receptor transcription pathway PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ESR-mediated signaling Extra-nuclear estrogen signaling SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 GAS8 GATA6-AS1 lncRNA p-2S-SMAD2,3:GATA6-AS1 lncRNA:GATA6 gene AS160:IRAP Phospho AS160:14-3-3 p-5S,T642-AS160:IRAP p-5S,T642-AS160:14-3-3:IRAP SMAD2,3 and GATA6-AS1 lncRNA bind the GATA6 gene 14-3-3 binds p-5S,T642-AS160 (TBC1D4) p-AKT1,p-AKT2 phosphorylates AS160 (TBC1D4) CTBP1,CTBP2 binds ZEB1 CD274 mRNA binds miR-142-5p RISC Expression of GATA6 in definitive endoderm CTBP1,CTBP2 binds CDH1 gene promoter SMO translocates to the cilium Formation of intermediate mesoderm Formation of the nephric duct Spry regulation of FGF signaling Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells Cardiogenesis Receptor-type tyrosine-protein phosphatases NTF3 activates NTRK3 signaling Signaling by NTRK3 (TRKC) Activated NTRK3 signals through PLCG1 Activated NTRK3 signals through RAS Activated NTRK3 signals through PI3K NTRK3 as a dependence receptor L13a-mediated translational silencing of Ceruloplasmin expression Translation initiation complex formation Formation of a pool of free 40S subunits Formation of the ternary complex, and subsequently, the 43S complex Ribosomal scanning and start codon recognition GTP hydrolysis and joining of the 60S ribosomal subunit Inactivation of CDC42 and RAC1 RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle PLC-gamma1 signalling Retrograde neurotrophin signalling NGF-independant TRKA activation TRKA activation by NGF PI3K/AKT activation Signalling to STAT3 Downregulation of SMAD2/3:SMAD4 transcriptional activity Germ layer formation at gastrulation Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane AURKA Activation by TPX2 Intra-Golgi traffic Signaling by membrane-tethered fusions of PDGFRA or PDGFRB Signaling by FLT3 fusion proteins Signaling by FGFR2 fusions RAF/MAP kinase cascade RET signaling NPAS4 regulates expression of target genes Formation of the ureteric bud Ca2+ pathway EPHB-mediated forward signaling Telomere Extension By Telomerase Formation of the beta-catenin:TCF transactivating complex Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence TSHR binds TSH/Thyrostimulin Signaling by ALK ALK mutants bind TKIs ASP-3026-resistant ALK mutants NVP-TAE684-resistant ALK mutants alectinib-resistant ALK mutants brigatinib-resistant ALK mutants ceritinib-resistant ALK mutants crizotinib-resistant ALK mutants lorlatinib-resistant ALK mutants MDK and PTN in ALK signaling Signaling by cytosolic FGFR1 fusion mutants Signaling by FGFR1 in disease Regulation of PTEN stability and activity Suppression of apoptosis COPII-mediated vesicle transport Coactivators are recruited to liganded PPARG:RXRA heterodimer PPARA activates gene expression Transcriptional regulation of white adipocyte differentiation SUMOylation of intracellular receptors Regulation of PTEN gene transcription MECP2 regulates transcription factors MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis Transcriptional regulation of brown and beige adipocyte differentiation by EBF2

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 226
1Fase 15
·Pré-clínico11
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 43 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Carcinoma da tireoide raro

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 2 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

8 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

43 ensaios clínicos encontrados, 23 ativos.

Distribuição por fase
NCT07863765 · Enfortumab Vedotin for the Treatment of Unresectable or Meta…Em breve
PHASE2🇺🇸 Estados Unidos
NCT06790589 · COACH - Comparing Two Different Methods to Suppress Thyrotro…Em breve
PHASE2
NCT07529080 · Personalized Cancer Support (Thrive Track) to Manage the Emo…Em breve
NA🇺🇸 Estados Unidos
NCT06713057 · Efficacy of Organoid-Based Chemotherapy Drug Precision Scree…Em breve
PHASE2🇨🇳 China
NCT04171622 · Lenvatinib and Pembrolizumab for the Treatment of Stage IVB …Ativo
PHASE2🇺🇸 Estados Unidos
NCT04759911 · Selpercatinib Before Surgery for the Treatment of RET-Altere…Ativo
PHASE2🇺🇸 Estados Unidos
NCT04061980 · Encorafenib and Binimetinib With or Without Nivolumab in Tre…Ativo
PHASE2🇺🇸 Estados Unidos
NCT04544111 · PDR001 Combination Therapy for Radioiodine-Refractory Thyroi…Ativo
PHASE2🇺🇸 Estados Unidos
NCT04459273 · Prospective Exploratory Study of FAPi PET/CT With Histopatho…Ativo
PHASE1🇺🇸 Estados Unidos
NCT03914300 · Testing the Combination of Cabozantinib, Nivolumab, and Ipil…Ativo
PHASE2🇺🇸 Estados Unidos
NCT03449108 · LN-145 or LN-145-S1 in Treating Patients With Relapsed or Re…Ativo
PHASE2🇺🇸 Estados Unidos
NCT03181100 · Atezolizumab With Chemotherapy in Treating Patients With Ana…Ativo
PHASE2🇺🇸 Estados Unidos
NCT02713269 · Thermal Ablation and Spine Stereotactic Radiosurgery in Trea…Ativo
PHASE2🇺🇸 Estados Unidos
NCT02152995 · Trametinib in Increasing Tumoral Iodine Incorporation in Pat…Ativo
PHASE2🇺🇸 Estados Unidos
NCT01947023 · Dabrafenib and Lapatinib in Treating Patients With Refractor…Ativo
PHASE1🇺🇸 Estados Unidos
NCT05917067 · Fluorescence Imaging of the Parathyroid Glands of ChildrenConcluído
🇳🇱 Países Baixos
NCT04593277 · Interactive Survivorship Program for the Improvement of Heal…Concluído
NA🇺🇸 Estados Unidos
NCT05410821 · Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic…Concluído
PHASE1🇨🇳 China
NCT02592356 · Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on We…Concluído
NA🇺🇸 Estados Unidos
NCT02393690 · Iodine I-131 With or Without Selumetinib in Treating Patient…Concluído
PHASE2🇺🇸 Estados Unidos
NCT01811212 · Cabozantinib-S-Malate in Treating Patients With Refractory T…Concluído
PHASE2🇺🇸 Estados Unidos
NCT01709435 · Cabozantinib S-Malate in Treating Younger Patients With Recu…Concluído
PHASE1🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT01208051 · Cediranib Maleate With or Without Lenalidomide for the Treat…Concluído
PHASE1, PHASE2🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT00729157 · Aflibercept in Treating Patients With Recurrent and/or Metas…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00625846 · Pazopanib Hydrochloride in Treating Patients With Advanced T…Concluído
PHASE2🇦🇺 Austrália · 🇨🇳 China · Singapore +2
NCT00559949 · Selumetinib in Treating Patients With Papillary Thyroid Canc…Concluído
PHASE2🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT00381641 · Sunitinib Malate in Treating Patients With Thyroid Cancer Th…Concluído
PHASE2🇺🇸 Estados Unidos
NCT03510143 · Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer…UNKNOWN
NASouth Korea
NCT05003856 · Radiofrequency Ablation for the Treatment of Benign or Low R…Encerrado
NA🇺🇸 Estados Unidos
NCT05575440 · Evaluation of 18F-TFB PET/CT Scan in Patients With Different…Encerrado
🇺🇸 Estados Unidos
NCT03506048 · Lenvatinib and Iodine Therapy in Treating Patients With Radi…Encerrado
PHASE2🇺🇸 Estados Unidos
NCT03630120 · Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients…Encerrado
PHASE2🇺🇸 Estados Unidos
NCT03463889 · Gallium-68 Prostate Specific Membrane Antigen PET in Diagnos…Encerrado
PHASE2🇺🇸 Estados Unidos
NCT02062632 · Doxepin Hydrochloride in Treating Esophageal Pain in Patient…Encerrado
PHASE2🇺🇸 Estados Unidos
NCT04731740 · Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differe…Cancelado
PHASE2Russia
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
9 papers (10 anos)
#1

Chromophobe thyroid carcinoma: a distinct entity associated with TSC gene alterations.

Virchows Archiv : an international journal of pathology2026 Jan 02

Chromophobe thyroid carcinoma (CTC) is a rare thyroid carcinoma with distinct morphology, often occurring in patients with tuberous sclerosis complex (TSC). The molecular drivers remain poorly understood. We report two additional CTC cases and review the literature including genetic query. Patient 1, an 11-year-old boy, had a 10.3-cm bilateral thyroid mass with tumoral capsular and vascular invasion. Microscopically, the tumor showed trabecular and nested growth, prominent cell membranes, raisinoid nuclei, eosinophilic granular cytoplasm, and perinuclear halos resembling chromophobe renal cell carcinoma. The tumor expressed thyroid markers (TTF-1, PAX-8, thyroglobulin) and renal cell markers (colloidal iron, parvalbumin, CD117) with peripheral mitochondrial accentuation by anti-mitochondrial staining. A somatic TSC2 p.Y1650Cfs*4 frameshift mutation was identified. Patient 2, a 24-year-old woman, had a 3.8-cm infiltrative, angioinvasive right lobe tumor with similar morphology and marker expression and positive lymph nodes. Molecular analysis showed somatic TSC2 c.2071dupC p.R691Pfs*12 and TSC2 c.2353C > T p.Q785* mutations. A cBioPortal query (2285 cases) found TSC1 alterations in 2% and TSC2 in 1%, mostly deletions, enriched in poorly differentiated and anaplastic thyroid carcinomas. Literature review identified seven CTC cases; 42.8% had TSC association and 42.8% showed locoregional recurrence. Median follow-up of 36 months showed all patients alive. Common morphologic and immunophenotypic features were consistent; 85.7% exhibited vascular invasion. None harbored common mutations like BRAF p.V600E and RAS. CTC is a distinct, rare thyroid carcinoma often linked to TSC or TSC mutations, characterized by unique morphology and immunophenotype.

#2

Fine-Needle Aspiration Cytologic Diagnosis of Intrathyroidal Thymic Carcinoma: A Review of the Literature.

Diagnostic cytopathology2025 Oct

Intrathyroidal thymic carcinoma is a rare thyroid carcinoma characterized by thymic epithelial differentiation. Given its relatively favorable prognosis, it is essential to differentiate it preoperatively from other more aggressive tumors. Fine-needle aspiration is widely used for the preoperative diagnosis of thyroid nodules. However, there is limited information on the cytological diagnosis, and its cytomorphological features remain poorly characterized. We perform a literature review of intrathyroidal thymic carcinoma and briefly describe two cases to further characterize its cytological features.

#3

Postoperative Radiotherapy for Medullary Thyroid Cancer: A Meta-Analysis of Survival and Recurrence Outcomes.

Head &amp; neck2025 Oct

Medullary thyroid cancer (MTC) is a rare thyroid carcinoma that often presents at an advanced stage. The efficacy of adjuvant postoperative radiotherapy (PORT) in treating MTC remains a topic of debate. We aimed to assess whether PORT enhances survival outcomes in patients with MTC. We conducted a systematic review of databases, including EMBASE, PubMed, Cochrane Library, and CINAHL to identify relevant studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and local recurrence-free survival (LRFS) were extracted, and pooled analyses were performed using random-effects models. Ten studies were finally included. Two separate pooled analyses of OS revealed no statistically significant differences between the PORT and observation groups (HR 1.59, 95% CI 0.87-2.92 and HR 1.67, 95% CI 0.92-3.02, including two different National Cancer Database studies with overlapping periods, respectively). Similarly, no significant differences were noted for LRFS (HR 0.90, 95% CI 0.44-1.82; I2 = 0%, p = 0.442). Although PORT did not demonstrate significant differences in survival outcomes compared to observation, personalized treatment considerations are essential due to heterogeneity among high-risk patients. Further prospective studies are required to define optimal adjuvant treatment strategies for MTC.

#4

Spindle epithelial tumor with thymus-like element (SETTLE)-Report of a rare thyroid carcinoma.

Clinical case reports2024 Aug

Spindle epithelial tumor with thymus-like element should be included in the differential diagnosis of thyroid gland cancers, particularly in medullary carcinoma, younger patients and indolent clinical presentation, because it may influence treatment and prognosis.

#5

A Case of Cribriform-Morular Thyroid Carcinoma Presenting Without Thyroid Nodule.

JCEM case reports2024 Apr

Cribriform-morular thyroid carcinoma is a rare type of thyroid cancer. It has a strong association with familial adenomatous polyposis (FAP), a hereditary genetic disorder that predisposes individuals to the development of numerous polyps in the colon and rectum. We describe the case of a young female patient who presented with an enlarging goiter, notably without detectable thyroid nodules or masses on ultrasound, who after total thyroidectomy was found to have cribriform-morular thyroid carcinoma. This diagnosis led to genetic testing and diagnosis of FAP syndrome. We demonstrate that this rare thyroid carcinoma may present with nonsuspicious findings on sonographic evaluation while being a valuable harbinger in the diagnosis of FAP syndrome.

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Carcinoma da tireoide raro.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Carcinoma da tireoide raro e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

É um adenocarcinoma maligno que se origina nas células da glândula tireoide. Ele engloba subtipos incomuns como o folicular, papilar, medular, pouco diferenciado e o anaplásico.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

5 publicações do grafo RarasNet (PubMed) · 6 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. ORPHA:100088
    Orphanet
  2. GARD:19763
    GARD (NIH)
  3. Q18556131
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Carcinoma da tireoide raro. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/carcinoma-da-tireoide-raro

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Carcinoma da tireoide raro

ORPHA:100088 · MONDO:0015075
Prevalência
1-5 / 10 000
Ensaios
23 ativos
Início
Adult
Prevalência
12.7 (Worldwide)
MedGen
UMLS
C0549473
EuropePMC
Wikidata
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Dado público estruturado
fonte: Wikidata
Rara